We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

23andMe is cashing in on drugs it developed with your DNA. Should its customers get a cut?

16 64 0
14.01.2020

The Google-backed genetics firm licensed an antibody it identified and synthesized to treat psoriasis and other inflammatory diseases to Spanish drug maker Almirall SA after identifying the compound and shepherding it through animal testing itself, 23andMe announced last week. Almirall will conduct human testing and “commercialize the antibody for worldwide use.” The deal’s financial terms were not made public, but Almirall boasts annual revenues of nearly $1 billion and the ‘biologic’ drugs used to treat psoriasis are some of the most expensive medications in existence, costing patients up to $38,000 per year. It’s safe to say 23andMe has cashed in handsomely on its customers’ genetic material. Does it owe them anything?

The Almirall deal is the first time 23andMe has directly sold a product created from the genetic data of the 10........

© RT.com